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Abstract
Human erythrocytes express at the membrane level a p57 serine proteinase which cleaves C3, the third component of
complement. We demonstrated herein that human serum carries an inhibitory activity against this p57 membrane proteinase.
 .Purification allowed to identify this inhibitor as the a1-proteinase inhibitor a1-PI on the basis of its molecular weight,
antigenicity and amino acid sequence identity. Data demonstrated that a1-PI is the unique and strong serum inhibitor of the
p57 proteinase activity: inhibition studies showed that a1-PI inhibited p57 proteinase activity with a k value of 105 My1ass
sy1. Inhibition of p57 proteinase by a1-PI was due to formation of a SDS-stable complex between both components. We
suggest that inhibition of the membrane p57 proteinase activity by serum a1-PI may be involved in the regulation of C3
fragment generation andror in clearance in liver of C3b bearing immune complexes by erythrocyte-CR1. q 1998 Elsevier
Science B.V.
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1. Introduction
Human C3, the third component of complement, is
a pivotal molecule of the humoral immune system
involved in at least three different biological func-
tions. First, C3 is the main component of complement
whose activation, through classical or alternative
Abbreviations: a1-PI, a1-proteinase inhibitor; a1-AC, a1-
antichymotrypsin; C3, third component of complement; CHAPS,
3-3-cholamidopropyl dimethylammonio-1-propanesulfonate;
HPLC, high pressure liquid chromatography; kDa, kilodaltons;
PBS, phosphate-buffered saline; SDS-PAGE, sodium dodecyl
sulfate polyacrylamide gel electrophoresis
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w xpathways, leads to target cell lysis 1 . The first step
of C3 cleavage in C3b allows covalent deposition of
C3b fragment on cell surface and formation of the
membrane-attack complex on target cells. Second,
human C3 is involved in antigen presentation and
w xconsequently facilitates cellular immune response 2 .
Third, C3 is also involved in cell regulations. Indeed,
during C3 activation, different fragments, namely
w xC3a, C3b, C3bi, C3dg and C3d 3 , are generated and
react with specific cell-surface receptors, namely
C3aR, CR1, CR3, CR4 and CR2, respectively, to
w xtrigger regulation of cellular functions 4–6 . Thus,
proteinases which cleave C3 could, in one hand,
protect normal or tumor target cells against autolo-
gous complement lysis by preventing deposition of
activated C3b on their surface and on the other hand
0167-4889r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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generate andror modify C3 fragments and conse-
quently their biological functions on these cells.
These findings led us to analyze the structure and
the functions of C3-cleaving proteinases expressed on
w xhuman cells 7–11 . Among these membrane pro-
teinases, we previously identified a p57 membrane
serine proteinase which cleaved C3 in human ery-
w xthrocyte membranes 7,8 . Amino acid analysis of the
first 20 N-terminal amino acids of the purified p57
proteinase demonstrated 100% identity with residues
910–929 of erythrocyte ankyrin, a sequence localized
w xin its 62-kDa fragment 12 . In addition, p57 pro-
teinase and ankyrin share common antigenic determi-
nants as recognized by anti-ankyrin and anti-p57
antibodies, respectively. Furthermore, while purified
ankyrin did not carry any detectable proteinase activ-
ity, limited proteolysis of ankyrin by immobilized
chymotrypsin generated this C3-cleaving serine pro-
teinase activity.
As p57 is a membrane-associated proteinase ex-
w xpressed on red cell surface 13 identified by its
property to cleave C3 a serum protein, we tried to
determine whether serum components could regulate
the activity of this membrane serine proteinase.
In the present study, we demonstrated that serum
carries an inhibitory activity which prevents the
cleavage of C3 by p57 serine proteinase. This in-
hibitory activity was purified and identified as the
 .serum a1-proteinase inhibitor a1-PI . Our data in-
dicated that a1-PI was the unique and very efficient
serum inhibitor of the membrane p57 proteinase kass
5 y1 y1.s10 M s , by forming a covalent complex.
These specific properties of a1-PI led us to suggest
that this proteinase inhibitor could play in vivo a role
in events associated to generation andror functions
of C3 fragments by the p57 C3-cleaving proteinase.
2. Materials and methods
2.1. Materials
Human serum was obtained from different healthy
donors at the Fondation Nationale de la Transfusion
 .Sanguine Hopital Saint-Antoine, Paris . Human C3ˆ
was purified from human serum according to Ham-
w xmer et al. 14 . P57 proteinase was purified from
membranes of human red blood cells as previously
described and the solubilized purified enzyme was
w xused in this assay 12 . Purified a1-PI was active-site
w xtitrated as described by Salvesen and Nagase 15 .
Pure and 95% active human a1-antichymotrypsin
 .a1-AC was from Calbiochem. Other inhibitors were
from Sigma.
2.2. P57 C3-clea˝ing acti˝ity
C3 was 125I-labeled with a specific activity of
9.104 cpm mgy1, using immobilized Iodogen method
 .Pierce . P57 C3-cleaving activity was measured, as
w x 125 previously described 12 . Briefly, I-C3 15 000
. w xcpm was incubated with 10 ml of purified p57 8,12
in 50 mM Tris–HCl, 1 mM 3-3-cholamidopropyl
 .dimethylammonio-1-propanesulfonate CHAPS at
pH 7, for 2 h at 378C. The reaction was stopped by
addition of 10 ml SDS-sample buffer and heating at
1008C for 3 min. Samples were submitted to 10%
sodium dodecyl sulfate polyacrylamide gel elec-
 .trophoresis SDS-PAGE under reducing conditions
w x16 and to autoradiography. Inhibitory activity of
samples was determined by preincubating 10 ml of
p57 with 15 ml of inhibitor or columns fractions for
15 min at room temperature, before incubation with
125  .10 ml of I-C3 15 000 for 2 h at 378C. Proteinase
activity was quantitated using an Ultroscan 2202
LKB laser densitometer as described by Jean et al.
w x10,11 .
2.3. Purification of p57 proteinase inhibitor
All the steps described below were performed at
48C, except for high pressure liquid chromatography
 .HPLC which was carried out at room temperature
 .using an LKB HPLC system. Human serum 35 ml
was precipitated with solid ammonium sulfate be-
tween 40% and 60% saturation for 4 h and cen-
trifuged. Then, precipitated proteins were dissolved
in 25 ml of 50 mM sodium phosphate, pH 5.8 buffer
.A and dialyzed overnight against buffer A. The
dialyzed fraction was then applied to a SP-Sephadex
 .  .C-50 column 2.5=18 cm Pharmacia equilibrated
with buffer A. Fractions containing p57 inhibitory
activity were found in the void volume. These frac-
tions were brought to 1.5 M NaCl and loaded, at 0.8
ml miny1, onto a phenyl-Sepharose CL-4B column
 .  .1.5=12 cm Pharmacia equilibrated with 1.5 M
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NaCl in buffer A. Fractions containing p57 inhibitory
activity were found in the void volume. These frac-
tions were dialyzed against Tris–HCl 50 mM, pH 7
 . y1buffer B , concentrated and applied at 0.7 ml min
 .on a DEAE-Memsep 1000 HP column Millipore
equilibrated with buffer B. The column was washed
with buffer B and proteins were eluted with a 0–0.5
M NaCl linear gradient in 20 ml of buffer B. Frac-
tions containing p57 proteinase inhibitory activity
were pooled and dialyzed against buffer B and loaded
 .onto a Mono Q HR 5r5 column Pharmacia equili-
brated with buffer B at 0.5 ml miny1. Proteins were
eluted with a 0–0.5 M NaCl linear gradient in 15 ml
of buffer B. Fractions with p57 proteinase inhibitory
activity were pooled and stored at y808C. Protein
concentrations were determined using the bicin-
 .choninic acid reagent Pierce . Proteins in gel were
 .stained with silver staining Bio-Rad . In immunoblot
analysis, proteins were submitted to 10% SDS-PAGE,
under reducing conditions, electrotransferred and im-
munoblotted using a polyclonal anti-human a1-PI
 .Ab Dako in the presence of 150 mM NaCl, as
w xpreviously described 17 .
2.4. Determination of the apparent rate inhibition
constant kass
k was measured under second-order conditionsass
 .with equimolar concentrations 50 nM of both p57
proteinase and a1-PI as described by Salvesen and
w xNagase 15 . Briefly, P57 and a1-PI were combined
at room temperature, samples were withdrawn at
 . 125  .timed intervals 2 min , assayed with I-C3 1 mM
for 30 min at 378C. Samples were then submitted to
SDS-PAGE under reducing conditions. Residual p57
C3-cleaving activity was determined by counting
lower molecular mass C3 fragments, in gel slices
using a LKB gamma counter. k was calculatedass
 .  .according to the following equation: 1rE s 1rE0
qk t, where E, E and t represent enzyme concen-ass 0
tration, initial enzyme concentration and time, respec-
tively.
2.5. Depletion of a1-PI from human serum
a1-PI was removed from phosphate-buffered saline
 .  y1.PBS -diluted human serum 200 mg ml as de-
w xscribed by Schechter et al. 18 . Briefly, human serum
was first preadsorbed with 15 mg of protein A–Sep-
 .harose Pharmacia for 2 h at 48C, then a1-PI was
 .depleted from human serum 500 ml with 100 mg of
the IgG fraction of anti-a1-PI Ab, bound to 15 mg of
protein A–Sepharose. Adsorptions were performed in
overnight incubations at 48C.
2.6. SDS-stable complex formation
SDS-stable p57ra1-PI complexes were analyzed
 .by incubating 30 ml of p57 proteinase 18 nM final
with 15 ml of PBS-diluted human serum 42 nM final
. of a1-PI or with 15 ml of purified a1-PI 42 nM
.final of a1-PI at 378C for 30 min. Then samples
were heated at 1008C in SDS-sample buffer and
submitted to 10% SDS-PAGE under non reducing
conditions. Complexes were detected on im-
munoblots with a polyclonal anti-a1-PI Ab.
3. Results
3.1. Identification of serum a1-PI as the serum
inhibitor of the p57 C3-clea˝ing proteinase
Preliminary analysis suggested that human serum
carried an inhibitory activity of the membrane p57
C3-cleaving proteinase. Thus, this inhibitory activity
was purified by a four-step procedure on SP-Sep-
hadex C-50, phenyl-Sepharose CL-4B, DEAE-Mem-
sep 1000 HP and Mono Q HR 5r5 columns Fig.
.1A , as detailed in Section 2. The different steps of
purification are summarized in Table 1. Protein pu-
rification demonstrated the presence in the serum of
an unique inhibitory activity of the C3-cleaving activ-
 .ity of p57 proteinase Fig. 1B . This inhibitory activ-
ity was carried by a component characterized by an
apparent molecular weight of 56 kDa on SDS-PAGE
 .under reducing conditions Fig. 1C, lane 2 . Amino
acid analysis of the first 10 N-terminal amino-acids
of the purified p56 proteinase inhibitor was deter-
mined as E-D-P-Q-G-D-A-A-Q-K, which is 100%
identical to the N-terminal sequence of human serum
w xa1-PI 19,20 . Immunoblotting assay with polyclonal
anti-human a1-PI Ab also demonstrated that the p56
serum inhibitor was antigenically related to human
 .a1-PI Fig. 1C, lane 3 . Altogether, these data sup-
ported that serum a1-PI was the unique serum in-
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 .Fig. 1. Purification and analysis of the p57 proteinase inhibitor. A Purification of the serum inhibitor of the C3-cleaving p57 proteinase
 .  .was performed by fractionation of human serum 35 ml with ammonium sulfate and by chromatography on SP-Sephadex C-50 a ,
 .  .  .phenyl-Sepharose CL-4B b , DEAE-Memsep 1000 c and Mono Q HR 5r5 d . Fractions containing the inhibitory activity are indicated
 . 125  .  .  .  .by solid bar. B I-C3 15 000 cpm was incubated alone lane 1 , with 10 nM of p57 proteinase lane 2 , with p57 proteinase 10 nM
 .  .preincubated with semi-purified inhibitor from phenyl-Sepharose step lane 3 , and with p57 proteinase 10 nM preincubated with 50 nM
 .of purified inhibitor lane 4 . Inhibition of p57 proteinase C3-cleaving activity was analyzed by SDS-PAGE under reducing conditions
 .  .  .  .and autoradiography. C Silver staining of purified inhibitor 800 ng lane 2 . Anti-a1-PI immunoblot of the purified inhibitor 500 ng
 .  .lane 3 . Molecular mass markers Lane 1 .
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Table 1
Purification of p57 proteinase inhibitor from human serum
Step Volume Protein Total activity Specific activity Yield Purification
y1 .  .  .  .  .  .ml mg units units mg % fold
Serum 35 2000 191 0.1 100 1
40%–60% Ammonium sulfate 30 495 85 0.2 45 2
SP-Sephadex C-50 43 122 63 0.5 30 5
Phenyl-Sepharose CL-4B 53 28 44 1.6 23 16
DEAE-Memsep 1000 HPLC 4 3.3 19 5.8 10 58
Mono Q HR 5r5 HPLC 1.5 0.55 10 21 5 210
Table 2
Effect of proteinase inhibitors on p57 proteinase activity
 .Inhibitors Concentration in the inhibition assay Proteinase activity % of control
none y 100
TLCK 50 mM 100
TPCK 50 mM 100
3–4 DCI 50 mM 0
PMSF 0.5 mM 0
a1-AC 50 nM 100
Aprotinin 50 nM 85
a1-PI 50 nM 0
Proteolytic activity was measured by determining the production of fragments generated from 125I-C3, using an LKB laser densitometric
 .scanner. The effect of inhibitors is expressed as percent of proteinase activity without inhibitors control . P57 proteinase was 10 nM in
the inhibition assays.
hibitor of the membrane p57 C3-cleaving proteinase
activity.
3.2. Serum a1-PI is an efficient inhibitor of the
membrane p57 C3-clea˝ing proteinase
Several proteinase inhibitors were tested on puri-
fied p57 C3-cleaving proteinase. As shown in Table
 .2, purified a1-PI 50 nM fully inhibited p57 pro-
 .teinase activity, while a1-AC 50 nM , another serum
proteinase inhibitor homologous to a1-PI, had no
significant inhibitory effect. Higher concentrations of
 .  .3–4 DCI 50 mM or PMSF 500 mM were required
to fully inhibit the p57 proteinase activity. Other
 .proteinase inhibitors as TLCK 50 mM and TPCK
 .50 mM did not inhibit the p57 C3-cleaving pro-
teinase activity. Furthermore, determination of p57
proteinase activity in the presence of a1-PI, at differ-
ent times and graphical analysis of the data obtained
using linear regression allowed to determine a kass
Fig. 2. Determination of the apparent rate inhibition constant
 .k for inhibition of p57 proteinase by purified a1-PI. Equimo-ass
 .lar concentrations 50 nM of p57 proteinase and a1-PI were
mixed and residual p57 proteinase activity was assayed with
125  .I-C3 at timed intervals 2 min . k was calculated as de-ass
scribed in Section 2.
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 .  .Fig. 3. Complex formation between p57 proteinase and serum a1-PI. A P57 was incubated with purified a1-PI lane 4 , with human
 .  .  .serum lane 5 , and with a1-PI immunodepleted human serum lane 6 using a 2.5:1 molar ratio of a1-PI to p57. The a1-PI 56 kDa
 .  .  .and a1-PIrp57 proteinase complex 110 kDa are indicated by arrows. In control, human serum alone lane 1 , purified a1-PI lane 2 ,
 .a1-PI-immunodepleted human serum lane 3 . a1-PI and a1-PIrp57 proteinase complexes were analyzed by SDS-PAGE under
 . 125  .reducing conditions and detected by immunoblotting using polyclonal anti-human a1-PI Ab. B I-C3 15 000 cpm was incubated
 .  .  .alone lane 1 , with 10 nM of p57 lane 2 , with 10 nM of p57 preincubated with a1-PI immunodepleted human serum lane 3 , with 10
 .  .nM of p57 preincubated with human serum lane 4 , and with 10 nM of p57 proteinase preincubated with purified a1-PI lane 5 .
Inhibition of p57 C3-cleaving activity was analyzed by SDS-PAGE under reducing conditions and detected by autoradiography.
5 y1 y1  .value of 10 M s Fig. 2 . These data supported
that serum a1-PI was a very efficient inhibitor of the
membrane p57 C3-cleaving proteinase.
3.3. Complex-formation between membrane p57 pro-
teinase and serum a1-PI
It was demonstrated by others that a1-PI inhibited
activity of serine proteinases by forming covalent
w xSDS-stable complexes 21 . Thus, the interaction of
a1-PI with the p57 C3-cleaving proteinase was ana-
lyzed by SDS-PAGE. As shown in Fig. 3A, incuba-
tion of the purified p57 proteinase with human serum
 .led to the formation of a SDS-stable complex lane 5
with a molecular mass of 110 kDa corresponding to
 .the molecular mass of a1-PI 56 kDa and of p57
 .proteinase 57 kDa complex. Complex formation
 .was also observed with purified a1-PI lane 4 . In
addition, no complex formation was detected when
p57 proteinase was incubated with a1-PI immunode-
 .pleted human serum lane 6 . Presence of a1-PI in
 .human serum lane 2 and its absence in a1-PI
 .immunodepleted serum lane 3 were controled. In
 .these conditions Fig. 3B , human serum fully inhib-
 .ited p57 proteinase activity lane 4 , as well as puri-
 .fied a1-PI lane 5 , while a1-PI immunodepleted
 .human serum did not lane 3 . These data supported
that a1-PI is the unique serum component which
inhibits the membrane p57 C3-cleaving proteinase by
forming a SDS-stable complex.
4. Discussion
Human erythrocyte membranes carry a p57 serine
w xproteinase which specifically cleaves human C3 7,8 .
More recently, we demonstrated that this p57 serine
proteinase was antigenically and structurally related
w xto the 62-kDa fragment of human ankyrin 12 . This
interaction between a membrane proteinase and a
serum component as C3 led us to investigate whether
the proteolytic activity of p57 could be regulated by
serum inhibitors.
We herein demonstrated that human serum carried
an inhibitory activity of the p57 C3-cleaving pro-
teinase activity. Purification of this inhibitory activity
demonstrated that it was carried by an unique serum
component, characterized by an apparent molecular
weight of 56 kDa and identified as the a1-PI on the
basis of its N-terminal amino acid sequence and
antigenic determinant identities. These results were
obtained using samples of human serum from differ-
ent healthy donors. Depletion of a1-PI from human
serum by specific anti-a1-PI antibodies confirmed
that this is the unique serum inhibitor of the p57
C3-cleaving proteinase.
( )F. Rodrigues-Lima et al.rBiochimica et Biophysica Acta 1402 1998 131–138 137
In addition, a1-PI appeared as the unique, very
specific and strong serum inhibitor of the p57 C3-
cleaving proteinase. Indeed, this inhibition was char-
acterized by a k value of 105 My1 sy1. This kass ass
value is similar to the k reported for inhibition ofass
 5rat mast cell proteinase by a1-PI k s2=10ass
y1 y1. w xM s 22 and to k values calculated for otherass
strong serine proteinase-protein inhibitor interactions
 5 y1 y1. w xk )10 M s 15 .ass
The mechanism of inhibition of the p57 serine
membrane proteinase by a1-PI is more likely due to
formation of a SDS-stable complex characterized by
an apparent molecular weight of 110 kDa, between
both molecules. Such mechanism is in agreement
with the properties of a1-PI to form complex with
serine proteinases present in various biological sys-
w xtems 21 . Indeed, a1-PI inhibits proteinase activity
of neutrophil elastase, cathepsin G or a subtilisin-like
w xproteinase, the latter being present in brain 23 . In
serum, a1-PI could regulate the proteolytic activity
w x w xof anionic trypsin 24 , chymases 18 and rat mast
w xcell 22 proteinases. a1-PI also inhibits human tis-
sue kallikrein, a proteinase involved in hypertension
and inflammation, by also forming SDS-stable com-
w xplex in a slow progressive process 25 . Our data
represent the first demonstration that a1-PI could
also regulate the activity of a membrane-associated
serine C3-cleaving proteinase.
The physiological significance of the regulation of
the p57 C3-cleaving proteinase activity by a1-PI
remains unknown. However, we speculate that this
regulation could take place in the erythrocyte-CR1
immune complex clearance system. Indeed, it is well
known that while erythrocytes carry few CR1
molecules, the predominance of erythrocytes in blood
render this cell type the major locus of intravascular
CR1. Thus, erythrocyte-CR1 participates strongly to
clearance of immune complexes in a complement-de-
w xpendant fashion 26 : the complexes remain bound to
erythrocyte until the cells traverse the portal circula-
tion; then, immune complexes are removed from the
cells or these cells which bear large numbers of
complexes were removed from the circulation by
w xadherence to reticuloendothelial cells 27 . In this
system, serum a1-PI will prevent the activity of the
p57 C3-cleaving serine proteinase expressed on ery-
throcyte surface during transportation of C3b bearing
immune complexes. Then, in the liver, serum a1-PI
molecules may be inhibited by liver components and
p57 serine proteinase generated from ankyrin may
cleave the C3b associated to immune complexes to
release these latter from red cell surface. Among the
liver components which may interact with p57 pro-
teinase–a1-PI complex, one good candidate could be
the receptor for serpin-complex identified in hep-
w xatoma cells by Perlmutter et al. 28 . These authors
suggested that the receptor for serpin-enzyme com-
plex present in these cells may be involved in clear-
ance of certain a1-PI–protease complexes. Our find-
ings should be also explored in pathological disor-
ders, e.g., systemic lupus erythematosus. Another
possibility may be that serum a1-PI could control
the generation of C3 fragments in situ, by preventing
serum C3 or C3b cleavage by membrane-associated
p57 serine proteinase. Further studies are needed to
explore these hypothesis.
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